PSE
4.11.2016 17:05:12 CET | Business Wire | Press release
Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced the winners of the prestigious PSE Model-Based Innovation (MBI) Prize for 2016.
PSE, providers of the world-leading gPROMS® process modelling platform, awards an annual €3000 winner’s prize and two runners-up prizes of €1000 each for the most innovative use of advanced process modelling techniques in support of published research. The prizes will be awarded at a reception on Wednesday 16 November at the AIChE Annual Meeting in San Francisco.
The winners of the main prize are Jose Romagnoli, Navid Ghadipasha and Aryan Geraili of Louisiana State University, Carlos Castor Jr and Wayne Reed of Tulane University, and Michael Drenski of Advanced Polymer Monitoring Technologies, Inc., for their paper Combining On-Line Characterization Tools with Modern Software Environments for Optimal Operation of Polymerization Processes, published in Processes 2016.
The judges summarised the research presented in the paper as “an excellent piece of work demonstrating an integrated framework for the dynamic modelling, simulation, estimation, optimisation and feedback control of a polymerisation process”.
Runners up were Ioscani Jimenez del Val of University College Dublin, Yuzhou Fan of Technical University of Denmark and Dietmar Weilguny of Symphogen A/S, Denmark, for their paper Dynamics of immature mAb glycoform secretion during CHO cell culture: An integrated modelling framework , and Yanan Cao and Christopher Swartz of McMaster University and Jesus Flores-Cerrillo and Jingran Ma of Praxair Inc. for their paper Dynamic Modeling and Collocation-Based Model Reduction of Cryogenic Air Separation Units . Full details can be found on the PSE website .
The prize is judged by team of leading academics in the field of process systems engineering, Prof. Stratos Pistikopoulos (chair) of Texas A&M Energy Institute, Associate Prof. Michael Georgiadis of the Aristotle University of Thessaloniki, Greece and Prof. Eva Sorensen of University College London.
gPROMS is widely used throughout the chemicals, energy, petrochemical, food and pharmaceuticals sectors, including in some 200 academic organisations. Mark Matzopoulos, deputy MD, says “PSE works closely with academic communities around the world to foster innovation, through our academic programme, the MBI Prize, our Partnerships for Advanced Process Modelling and the PSE Academic Teaching Highway (PATH). We congratulate our winners on the quality of their work.”
View source version on businesswire.com: http://www.businesswire.com/news/home/20161104005758/en/
Contact:
Process Systems Enterprise
Contact:
Kate Burness
+44-20-8563-0888
k.burness@psenterprise.com
Editors:
www.psenterprise.com/news/pr161102
Link:
Social Media:
https://www.facebook.com//Process-Systems-Enterprise-Limited-PSE-194030330653358/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom